Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PREP | P48147 | 4/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780263 | 0.97 | HSD17B10 (0.58) | HSD17B10PREPKLK7UCHL1NPC1 | |
| SCHEMBL2960273 | 0.96 | PREP (0.57) | HSD17B10PREPFKBP1AKLK7 | |
| SCHEMBL6201175 | 0.91 | PREP (0.58) | HSD17B10PREPKLK7UCHL1 | |
| SCHEMBL6201170 | 0.91 | PREP (0.58) | HSD17B10PREPKLK7UCHL1 | |
| SCHEMBL3394990 | 0.86 | HSD17B10 (0.56) | HSD17B10KLK7UCHL1 | |
| SCHEMBL3394995 | 0.86 | HSD17B10 (0.56) | HSD17B10KLK7UCHL1 | |
| SCHEMBL16531226 | 0.86 | FKBP1A (0.70) | PREPFKBP1AKLK7 | |
| SCHEMBL13257218 | 0.86 | FKBP1A (0.70) | PREPFKBP1AKLK7 | |
| SCHEMBL221644 | 0.86 | FKBP1A (0.70) | PREPFKBP1AKLK7 | |
| SCHEMBL10556342 | 0.85 | PREP (0.65) | PREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| EP-1968590-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | HSD17B10 3400/4885PREP 3355/4885FKBP1A 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.